Advertisement

The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data

Published:December 05, 2017DOI:https://doi.org/10.1016/j.ejca.2017.10.023

      Highlights

      • Men without close relatives were found to receive less opioids.
      • Older men were found to receive less ADT, opioids and anxiolytics.
      • Opioids were prescribed to 72% of the men in the cohort at death.
      • use of medications for mood disorders was found to increase in terminal disease.
      • Low education was found to increase the probability to receive opioids.

      Abstract

      Background

      Symptoms of terminal cancer have previously been reported as undertreated. The aim of this study was to assess the use of palliative medications before death from prostate cancer.

      Methods

      This Swedish register study included men who died from 2009 to 2012 with prostate cancer as the underlying cause of death. We assessed the proportion who collected a prescription of androgen deprivation therapy, non-steroidal anti-inflammatory drugs, paracetamol, opioids, glucocorticoids, antidepressants, anxiolytics and sedative-hypnotics and the differences in treatment related to age, time since diagnosis, educational level, close relatives and comorbidities. Data were collected from 3 years before death from prostate cancer.

      Results

      We included 8326 men. The proportion who received opioids increased from 30% to 72% during the last year of life, and 67% received a strong opioid at the time of death. Antidepressants increased from 13% to 22%, anxiolytics from 9% to 27% and sedative-hypnotics from 21% to 33%. Men without close relatives and older men had lower probability to receive opioids (odds ratio [OR]: 0.56, 95% confidence interval [CI]: 0.47–0.66 for >85 years versus <70 years) and (OR 0.78, 95% CI: 0.66–0.92 for unmarried without children versus married with children).

      Conclusion

      Our results represent robust epidemiological data from Sweden for comparison of palliative care quality between countries. The findings indicate that men without close relatives and older men are disadvantaged with respect to the treatment of cancer pain and need closer attention from health care providers and highlight the importance to identify psychological distress in terminal prostate cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Muralidharan A.
        • Smith M.T.
        Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.
        Inflammopharmacology. 2013; 21: 339-363
        • Watts S.
        • Leydon G.
        • Birch B.
        • Prescott P.
        • Lai L.
        • Eardley S.
        • et al.
        Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates.
        BMJ Open. 2014; 4e003901
        • Mitchell A.J.
        • Chan M.
        • Bhatti H.
        • Halton M.
        • Grassi L.
        • Johansen C.
        • et al.
        Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.
        Lancet Oncol. 2011; 12: 160-174
        • Mercadante S.
        • Aielli F.
        • Adile C.
        • Ferrera P.
        • Valle A.
        • Cartoni C.
        • et al.
        Sleep disturbances in patients with advanced cancer in different palliative care settings.
        J Pain Symptom Manage. 2015; 50: 786-792
        • Nguyen P.L.
        • Alibhai S.M.
        • Basaria S.
        • D'Amico A.V.
        • Kantoff P.W.
        • Keating N.L.
        • et al.
        Adverse effects of androgen deprivation therapy and strategies to mitigate them.
        Eur Urol. 2015; 67: 825-836
        • Donovan K.A.
        • Walker L.M.
        • Wassersug R.J.
        • Thompson L.M.
        • Robinson J.W.
        Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners.
        Cancer. 2015; 121: 4286-4299
        • Greco M.T.
        • Roberto A.
        • Corli O.
        • Deandrea S.
        • Bandieri E.
        • Cavuto S.
        • et al.
        Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer.
        J Clin Oncol. 2014; 32: 4149-4154
        • Nakash O.
        • Levav I.
        • Aguilar-Gaxiola S.
        • Alonso J.
        • Andrade L.H.
        • Angermeyer M.C.
        • et al.
        Comorbidity of common mental disorders with cancer and their treatment gap: findings from the World Mental Health Surveys.
        Psychooncology. 2014; 23: 40-51
        • Tomic K.
        • Sandin F.
        • Wigertz A.
        • Robinson D.
        • Lambe M.
        • Stattin P.
        Evaluation of data quality in the national prostate cancer register of Sweden.
        Eur J Cancer. 2015; 51: 101-111
        • Van Hemelrijck M.
        • Garmo H.
        • Wigertz A.
        • Nilsson P.
        • Stattin P.
        Cohort profile update: the national prostate cancer register of Sweden and prostate cancer data base-a refined prostate cancer trajectory.
        Int J Epidemiol. 2016; 45: 73-82
        • Vardy J.
        • Agar M.
        Nonopioid drugs in the treatment of cancer pain.
        J Clin Oncol. 2014; 32: 1677-1690
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Brelin S.
        • Fredheim O.M.
        • Loge J.H.
        • Skurtveit S.
        • Johannesen T.B.
        • Aass N.
        • et al.
        Opioids for outpatients with cancer in their last year of life: a nationwide pharmacoepidemiological study.
        J Opioid Manag. 2016; 12: 25-36
        • Mercadante S.
        • Arcuri E.
        Pharmacological management of cancer pain in the elderly.
        Drugs Aging. 2007; 24: 761-776
        • Jarlbaek L.
        • Hansen D.G.
        • Bruera E.
        • Andersen M.
        Frequency of opioid use in a population of cancer patients during the trajectory of the disease.
        Clin Oncol (R Coll Radiol). 2010; 22: 199-207
        • Borgsteede S.D.
        • Deliens L.
        • Zuurmond W.W.
        • Schellevis F.G.
        • Willems D.L.
        • Van der Wal G.
        • et al.
        Prescribing of pain medication in palliative care. A survey in general practice.
        Pharmacoepidemiol Drug Saf. 2009; 18: 16-23
        • Higginson I.J.
        • Gao W.
        Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study.
        J Clin Oncol. 2012; 30: 4373-4379
        • Nelson C.J.
        • Weinberger M.I.
        • Balk E.
        • Holland J.
        • Breitbart W.
        • Roth A.J.
        The chronology of distress, anxiety, and depression in older prostate cancer patients.
        Oncologist. 2009; 14: 891-899
        • Costantini M.
        • Ripamonti C.
        • Beccaro M.
        • Montella M.
        • Borgia P.
        • Casella C.
        • et al.
        Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients' life. Results of an Italian mortality follow-back survey.
        Ann Oncol. 2009; 20: 729-735
        • The National Board of Health and Welfare
        Nationella riktlinjer – Utvärdering 2016. Palliativ vård i livets slutskede. Indikatorer och underlag för bedömningar.
        2016 ([Accessed 29 June 2017])
        • Apolone G.
        • Corli O.
        • Caraceni A.
        • Negri E.
        • Deandrea S.
        • Montanari M.
        • et al.
        Pattern and quality of care of cancer pain management. Results from the cancer pain outcome research study group.
        Br J Cancer. 2009; 100: 1566-1574
        • Chinellato A.
        • Terrazzani G.
        • Debetto P.
        • Zambon P.
        • Guzzinati S.
        • Walley T.
        • et al.
        Retrospective analysis of opioid prescriptions in cancer patients in a northern Italian region.
        Br J Clin Pharmacol. 2006; 62: 130-133
        • Ziegler L.
        • Mulvey M.
        • Blenkinsopp A.
        • Petty D.
        • Bennett M.I.
        Opioid prescribing for patients with cancer in the last year of life: a longitudinal population cohort study.
        Pain. 2016; 157: 2445-2451
        • Berterame S.
        • Erthal J.
        • Thomas J.
        • Fellner S.
        • Vosse B.
        • Clare P.
        • et al.
        Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study.
        Lancet. 2016; 387: 1644-1656
        • Hamunen K.
        • Paakkari P.
        • Kalso E.
        Trends in opioid consumption in the Nordic countries 2002–2006.
        Eur J Pain. 2009; 13: 954-962
        • Aktas A.
        • Walsh D.
        • Hauser K.
        • Rybicki L.
        Should we cluster patients or symptoms? The myth of symptom clusters based on ‘depression, insomnia, pain’ and ‘depression, fatigue, pain’.
        BMJ Support Palliat Care. 2016; 6: 210-218
        • Lichtenthal W.G.
        • Nilsson M.
        • Zhang B.
        • Trice E.D.
        • Kissane D.W.
        • Breitbart W.
        • et al.
        Do rates of mental disorders and existential distress among advanced stage cancer patients increase as death approaches?.
        Psychooncology. 2009; 18: 50-61
        • Tang S.T.
        • Chen J.S.
        • Chou W.C.
        • Lin K.C.
        • Chang W.C.
        • Hsieh C.H.
        • et al.
        Prevalence of severe depressive symptoms increases as death approaches and is associated with disease burden, tangible social support, and high self-perceived burden to others.
        Support Care Cancer. 2016; 24: 83-91
        • Lissbrant I.F.
        • Garmo H.
        • Widmark A.
        • Stattin P.
        Population-based study on use of chemotherapy in men with castration resistant prostate cancer.
        Acta Oncol. 2013; 52: 1593-1601
        • van den Beuken-van Everdingen M.H.
        • de Rijke J.M.
        • Kessels A.G.
        • Schouten H.C.
        • van Kleef M.
        • Patijn J.
        High prevalence of pain in patients with cancer in a large population-based study in The Netherlands.
        Pain. 2007; 132: 312-320
        • Trama A.
        • Foschi R.
        • Larranaga N.
        • Sant M.
        • Fuentes-Raspall R.
        • Serraino D.
        • et al.
        Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: results from the EUROCARE-5 study.
        Eur J Cancer. 2015; 51: 2206-2216
        • Godtman R.
        • Holmberg E.
        • Stranne J.
        • Hugosson J.
        High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.
        Scand J Urol Nephrol. 2011; 45: 226-232